We are live on ! Find out more
DC

Decheng Capital Portfolio holdings

AUM $661M
1-Year Est. Return 299.97%
This Fund
S&P 500
This Quarter Est. Return
+66.02%
1 Year Est. Return
+299.97%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$746M
AUM Growth
+$388M
Cap. Flow
+$189M
Cap. Flow %
25.34%
Top 10 Hldgs %
93.39%
Holding
31
New
7
Increased
2
Reduced
2
Closed
9

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$223M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$36.4M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$9.04M
4
FDMT icon
4D Molecular Therapeutics
FDMT
+$8.87M
5
CYTK icon
Cytokinetics
CYTK
+$7.27M

Top Sells

Rank Stock Value
1
PACB icon
Pacific Biosciences
PACB
+$28.8M
2
IMGN
Immunogen Inc
IMGN
+$19.6M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$14.9M
4
ROIV icon
Roivant Sciences
ROIV
+$14.4M
5
ARGX icon
argenx
ARGX
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
1
DELISTED
Alpine Immune Sciences Inc
ALPN
$330M 44.22%
8,317,924
+1,234,636
+17% +$36.4M
CGON icon
2
CG Oncology
CGON
$6.41B
$240M 32.14%
+5,458,810
New +$223M
ZNTL icon
3
Zentalis Pharmaceuticals
ZNTL
$329M
$33.1M 4.44%
2,099,583
– –
ILMN icon
4
Illumina
ILMN
$29.2B
$17.7M 2.38%
132,681
+49,558
+60% +$6.64M
BYSI icon
5
BeyondSpring
BYSI
$48.7M
$17.7M 2.37%
4,958,143
– –
RCUS icon
6
Arcus Biosciences
RCUS
$3.4B
$16.4M 2.2%
869,790
– –
KRYS icon
7
Krystal Biotech
KRYS
$10.7B
$11.7M 1.57%
65,772
– –
FDMT icon
8
4D Molecular Therapeutics
FDMT
$515M
$11.1M 1.49%
+347,835
New +$8.87M
EQ icon
9
Equillium
EQ
$147M
$10.3M 1.38%
4,447,308
– –
PHAT icon
10
Phathom Pharmaceuticals
PHAT
$930M
$9.03M 1.21%
850,000
– –
MLTX icon
11
MoonLake Immunotherapeutics
MLTX
$1.59B
$8.37M 1.12%
+166,600
New +$9.04M
CRNX icon
12
Crinetics Pharmaceuticals
CRNX
$8.88B
$7.39M 0.99%
+157,958
New +$6.18M
TXG icon
13
10x Genomics
TXG
$5.97B
$7.35M 0.99%
195,835
-163,719
-46% -$7.19M
CYTK icon
14
Cytokinetics
CYTK
$10.8B
$6.59M 0.88%
+94,043
New +$7.27M
LEGN icon
15
Legend Biotech
LEGN
$3.68B
$4.84M 0.65%
+86,363
New +$5.21M
MRUS
16
DELISTED
Merus
MRUS
$4.58M 0.61%
+101,798
New +$4.13M
AURA icon
17
Aura Biosciences
AURA
$729M
$4.05M 0.54%
515,555
– –
HLTH
18
DELISTED
Cue Health Inc. Common Stock
HLTH
$1.7M 0.23%
8,980,909
– –
PYXS icon
19
Pyxis Oncology
PYXS
$184M
$1.39M 0.19%
326,810
– –
WHWK
20
Whitehawk Therapeutics
WHWK
$182M
$1.23M 0.17%
526,329
– –
WGS icon
21
GeneDx Holdings
WGS
$1.84B
$946K 0.13%
103,604
– –
ATRC icon
22
AtriCure
ATRC
$2.02B
$815K 0.11%
26,797
-19,462
-42% -$652K
ARGX icon
23
argenx
ARGX
$54.6B
– –
-27,429
Closed -$10.4M
LNTH icon
24
Lantheus
LNTH
$6.68B
– –
-92,196
Closed -$5.72M
PACB icon
25
Pacific Biosciences
PACB
$432M
– –
-2,940,361
Closed -$28.8M
1
2

Similar funds

FAM
Fulcrum Asset Management London, United Kingdom $662M AUM 48.09% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
HIG
Heritage Investment Group Pompano Beach, Florida $661M AUM 14.84% 1-Year Est. Return
RCG
Regatta Capital Group El Segundo, California $661M AUM 17.85% 1-Year Est. Return
FM
Freemont Management Vaud, Switzerland $661M AUM 60.48% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
AWA
Artemis Wealth Advisors New York $662M AUM 39.67% 1-Year Est. Return
UCMOK
United Capital Management of KS Salina, Kansas $660M AUM 50.85% 1-Year Est. Return

Decheng Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Decheng Capital held 31 positions worth $746M, up 108% from $358M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Decheng Capital deployed $189M of net new capital in Q1 2024, opening 7 new positions and adding to 2 existing holdings. Its largest new stake was CG Oncology: 5,458,810 shares worth $240M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was 10x Genomics, an estimated $7.19M trimmed.

  • Decheng Capital's largest Q1 2024 buy was CG Oncology: 5,458,810 shares worth $240M.
  • Decheng Capital added most to Alpine Immune Sciences Inc in Q1 2024, an estimated $36.4M increase.
  • Decheng Capital's biggest Q1 2024 reduction was 10x Genomics, cutting an estimated $7.19M.
  • Decheng Capital fully exited Pacific Biosciences in Q1 2024, selling an estimated $28.8M.
  • Decheng Capital's ten largest holdings make up 93% of its $746M portfolio in Q1 2024.
  • Decheng Capital opened 7 new positions and closed 9 in Q1 2024.
  • Decheng Capital's portfolio value rose 108% quarter-over-quarter to $746M.

Based on Decheng Capital's 13F filing for Q1 2024, filed 14 May 2024.